

# Micronutrients and enteric infections in African children: the effect of prophylactic micronutrient supplementation on morbidity and growth in human immunodeficiency virus infected and human immunodeficiency virus-uninfected children in South Africa

|  |  |  |
|--|--|--|
| <b>Submission date</b><br>30/03/2006   | <b>Recruitment status</b><br>No longer recruiting        | <input type="checkbox"/> Prospectively registered    |
| <b>Registration date</b><br>30/03/2006 | <b>Overall study status</b><br>Completed                 | <input type="checkbox"/> Protocol                    |
| <b>Last Edited</b><br>28/01/2019       | <b>Condition category</b><br>Infections and Infestations | <input type="checkbox"/> Statistical analysis plan   |
|  |  | <input checked="" type="checkbox"/> Results          |
|  |  | <input type="checkbox"/> Individual participant data |

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof M L Bennish

**Contact details**  
Africa Centre for Health and Population Studies  
P.O. Box 198  
Mtubatuba  
South Africa  
3935  
+27 (0)35 550 7502  
mbennish@africacentre.ac.za

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**  
NCT00133419

**Secondary identifying numbers**  
5U01 AI058371-05 (grant number); NIH/NIAD

## **Study information**

### **Scientific Title**

Micronutrients and enteric infections in African children: the effect of prophylactic micronutrient supplementation on morbidity and growth in human immunodeficiency virus infected and human immunodeficiency virus-uninfected children in South Africa

### **Study objectives**

Objective:

To compare the effect of three micronutrient supplements:

1. Vitamin A only,
2. Vitamin A and zinc,
3. A micronutrient mixture containing vitamins A, B, C, D, E, K, and calcium, copper, folate, iodine, iron, magnesium and zinc, on prevalent days of diarrhoea in three groups of children:
  - a. Human Immunodeficiency Virus (HIV)-infected children
  - b. HIV-uninfected children born to HIV-infected women
  - c. HIV-uninfected children born to women without HIV infection

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Not provided at time of registration

### **Study design**

A randomised, double blind, clinical controlled trial with three arms

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Not specified

### **Study type(s)**

Treatment

### **Participant information sheet**

### **Health condition(s) or problem(s) studied**

## Human Immunodeficiency Virus (HIV)

### Interventions

Children from each of the HIV status groups will be individually randomised to one of the three multivitamin/micronutrient arms:

1. Vitamin A only
2. Vitamin A and zinc
3. A micronutrient mixture containing vitamins A, B, C, D, E, K, and calcium, copper, folate, iodine, iron, magnesium and zinc

Randomisation will occur in blocks of six within each of the HIV status groups. This will result in assigning a pre-coded box filled with blister packets of seven micronutrient tablets each. Each child will use tablets from that same box throughout the study. Each type of tablet will appear and taste identical to ensure blinding of both mothers and field staff. The interval between testing and randomisation may vary depending on the time required to obtain HIV testing results. All children will, however, start their respective supplement at six months of age (+/- 14 days) and will continue with the supplements until they are 24 months of age (i.e. for approximately 18 months). Monitoring will continue throughout this time to determine the long-term impact of each supplementation.

### Intervention Type

Supplement

### Phase

Not Specified

### Drug/device/biological/vaccine name(s)

Micronutrient supplementation

### Primary outcome measure

The primary outcome measure is prevalent days of diarrhoea per child during the 18 months that children will receive supplements (from six to 24 months of age). Comparisons will be stratified by HIV status, and all three micronutrient regimens will be compared within these strata.

### Secondary outcome measures

No secondary outcome measures

### Overall study start date

01/07/1999

### Completion date

30/06/2005

## Eligibility

### Key inclusion criteria

1. Infants aged four to six months (stratified by HIV status)
2. Able to take oral preparations
3. Parent/guardian able to give consent

**Participant type(s)**

Patient

**Age group**

Child

**Lower age limit**

4 Months

**Upper age limit**

6 Months

**Sex**

Not Specified

**Target number of participants**

516

**Key exclusion criteria**

1. Documented micronutrient supplementation other than vitamin A in the preceding month
2. Less than 60% of mean weight for age by National Center for Health Statistics (NCHS) guidelines (micronutrient intervention obligatory according to World Health Organisation [WHO] guidelines for management of severely malnourished children)
3. Persistent diarrhoea (more than seven days) at the time of study enrolment
4. Exclusive breastfeeding
5. Infants in whom a second confirmatory HIV test cannot be obtained (when required)
6. Co-enrolment of the infant in other clinical intervention trials e.g. antibiotic or vaccine trials

**Date of first enrolment**

01/07/1999

**Date of final enrolment**

30/06/2005

**Locations****Countries of recruitment**

South Africa

**Study participating centre**

Africa Centre for Health and Population Studies

Mtubatuba

South Africa

3935

**Sponsor information**

**Organisation**

National Institute of Allergy and Infectious Diseases (NIAID) (USA)

**Sponsor details**

International Tropical Disease Research Network  
Division of Microbiology and Infectious Diseases (DMID)  
Room 5067  
6610 Rockledge Drive  
Bethesda  
United States of America  
20892

**Sponsor type**

Government

**Website**

<http://www.niaid.nih.gov/>

**ROR**

<https://ror.org/043z4tv69>

**Funder(s)****Funder type**

Government

**Funder Name**

National Institute of Allergy and Infectious Diseases (NIAID) (USA)

**Alternative Name(s)**

Instituto Nacional de Alergias y Enfermedades Infecciosas, National Institute of Allergy & Infectious Diseases, NIAID

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United States of America

**Results and Publications**

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

| Output type                     | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| <a href="#">Results article</a> | results | 27/06/2007   | 28/01/2019 | Yes            | No              |
| <a href="#">Results article</a> | results | 01/07/2009   | 28/01/2019 | Yes            | No              |
| <a href="#">Results article</a> | results | 18/03/2010   | 28/01/2019 | Yes            | No              |